ADDEX THERAPEUTICS LTD

Addex Therapeutics reports 2026 half‑year results, new funding for its GABAB cough program, and progress on Neurosterix schizophrenia trials—key insights for biotech investors.

Addex Therapeutics’ Swiss biotech stock has lost ~25% of investor value in a year, with negative P/E, low market cap and high volatility, warning investors of risky, unproven growth prospects.

Preclinical breakthrough for Addex Therapeutics’ GABAB PAM shows promise in an IPF cough model, hinting at new treatment options amid Swiss market volatility and cautious investor outlook.

Addex Therapeutics’ breakthrough Phase I schizophrenia trial and strong anti‑cough results could shift its volatile stock into a credible biotech contender.

Discover how Addex Therapeutics’ oral GABAB PAM shows strong anti‑tussive results in primates, promising a once‑daily, low‑side‑effect treatment for chronic cough.

Addex Therapeutics Ltd has experienced a significant 95.77% decline in stock value over the past five years, from 1.39 CHF to 0.0588 CHF, amidst broader market fluctuations and sector-specific challenges.

Addex Therapeutics Ltd is making significant strides in developing treatments for chronic cough, with promising preclinical data and upcoming presentations at key conferences.

Addex Therapeutics navigated a challenging financial year with strategic advancements in neurological disorders, including a successful Series A funding round and partnerships, despite a decline in stock value.